Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world.
  • Posted by Rachel Howard
  • January 18, 2018
  • Articles

New opportunities in emerging markets

New opportunities in emerging markets

Published in Pharma Exec January 2018 by Rachel Howard

The next billion patientsUntil recently, multinational pharmaceutical and life sciences companies have focused their clinical research efforts/clinical development programs almost exclusively on mature markets: North America, Europe and Japan in particular. However, rapid changes are underway in emerging markets. Firstly, we are seeing an expanding middle class. Virtually every emerging market, from Indonesia to Mexico and from China to Brazil, is witnessing an increase in the proportion of patients who now qualify as middle class, and wealth is increasing commensurately, enabling more individuals to afford essential care or purchase private health insurance. This growth is set to continue. In parallel, we are seeing an increased focus among emerging market governments on public healthcare reform: expanding their populations’ access to medicines by establishing universal healthcare coverage (such as JKN in Indonesia and Seguro Popular in Mexico) and deepening access by expanding formularies to include more drugs (despite these often being set in the context of aggressive cost containment measures).  Greater purchasing power and improved market access are growing the opportunity for innovative medicines in these markets.  The vast populations of many emerging markets mean they constitute a high proportion of the world’s "next billion patients", which pharma simply cannot afford to…

read more »

Understanding the chronic disease patient journey in emerging markets

Understanding the chronic disease patient journey in emerging markets

In this paper, we explore the chronic disease patient journey in emerging markets and provide you with the insights you require to identify the key inflection points in these rapidly changing and diverse regions.

With growing urban populations and increasing purchasing power, emerging markets remain an attractive prospect for growth. A high proportion of the urban emerging market population already suffers from chronic diseases and prevalence is set to further increase as lifestyles become closer to those in the West. The chronic disease patient is a critical stakeholder in emerging markets because they often have to pay for their healthcare out of pocket. Moreover, these markets often don’t have formal primary care systems, so the patient is the only constant in the journey. Understanding their journey is critical in order to best leverage these potential new markets.

read more »

  • Posted by Marc Yates
  • August 31, 2016
  • Articles

Understanding the Chronic Disease Patient Journey in Emerging Markets

Understanding the Chronic Disease Patient Journey in Emerging Markets

The benefits of understanding the patient journey are well documented in mature markets. But in emerging markets the patient journey is less understood. We recently presented a webinar hosted by Pharmaceutical Executive where we addressed the changing emerging market healthcare environment and explored the challenges and differences in the patient journey. In this article I wanted to share some of these learnings.

read more »

  • Posted by Julie Denny
  • June 21, 2016
  • Webinars

Understanding the Chronic Disease Patient Journey in Emerging Markets

Understanding the Chronic Disease Patient Journey in Emerging Markets

With growing urban populations and increasing purchasing power, emerging markets remain an attractive prospect for growth. A high proportion of the urban emerging market population already suffer from  chronic diseases and prevalence is set to further increase as lifestyles become closer to those in the West.
The chronic disease patient is a critical stakeholder in emerging markets because they often have to pay for their healthcare out of pocket. Moreover these markets often don’t have formal primary care systems, so the patient is the only constant in the journey. Understanding their journey is critical in order to fully exploit these potential new markets.

read more »

  • Posted by Julie Denny
  • April 5, 2016
  • Webinars

Understanding the Chronic Disease Patient Journey in Emerging Markets

Understanding the Chronic Disease Patient Journey in Emerging Markets

With growing urban populations and increasing purchasing power, emerging markets remain an attractive prospect for growth. A high proportion of the urban emerging market population already suffer from  chronic diseases and prevalence is set to further increase as lifestyles become closer to those in the West.
The chronic disease patient is a critical stakeholder in emerging markets because they often have to pay for their healthcare out of pocket. Moreover these markets often don’t have formal primary care systems, so the patient is the only constant in the journey. Understanding their journey is critical in order to fully exploit these potential new markets.

read more »